FX.co ★ Annexon Reports Promising Phase 2 Data For ANX007 In Geographic Atrophy Due To Dry AMD

Annexon Inc. (ANNX) has unveiled promising results from its Phase 2 ARCHER trial evaluating ANX007 for geographic atrophy (GA) associated with dry age-related macular degeneration (AMD). The data indicate that ANX007 effectively enhances visual protection and preserves central photoreceptor cells, particularly in a subgroup of patients with early-stage disease, as determined by the photoreceptor ellipsoid zone (EZ) in the central fovea.

Significant observations from the study highlight the superior vision loss protection ANX007 offers to patients with early-stage disease compared to the broader patient cohort over a 12-month period. Remarkably, among patients with less advanced disease, none (0 out of 56) of those treated monthly with ANX007 experienced a loss of 15 letters, equivalent to three lines on an eye chart. This contrasts sharply with the 17% (10 out of 59) of patients in the sham group, resulting in a nominal p-value of 0.0013.

Across the entire patient population, 6% (5 out of 89) of those treated monthly with ANX007 experienced a 15-letter loss, compared to 21% (19 out of 89) in the sham group, reflecting a nominal p-value of 0.0021. Furthermore, ANX007 showcased improved performance in safeguarding against ellipsoid zone (EZ) loss in central regions, particularly among patients with relatively intact EZ at the outset. Specifically, there was a 61% reduction in EZ loss in patients with less than 80% initial EZ loss, and a 48% reduction among those with less than 98% EZ loss at baseline, when compared to the sham group.